James Emigh - Acura Pharmaceuticals Vice President - Corporate Development
| ACURDelisted Stock | USD 0.05 0.00 0.00% |
President
Mr. James F. Emigh serves as a Vice President of Corporationrationrate Development of Acura Pharmaceutical Technologies, Inc. Since October 2011. From April 2004 to October 2011, Mr. Emigh was our Vice President of Marketing and Administration. Prior to such time, Mr. Emigh was our Vice President of Sales and Marketing. Mr. Emigh joined us in May, 1998, serving first as Executive Director of Customer Relations and then as Vice President of Operations since 2011.
| Age | 61 |
| Tenure | 13 years |
| Phone | 847 705 7709 |
| Web | https://www.acurapharm.com |
Acura Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3842) % which means that it has lost $0.3842 on every $100 spent on assets. This is way below average. Acura Pharmaceuticals' management efficiency ratios could be used to measure how well Acura Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 105 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharmaceuticals has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | PRESIDENT Age | ||
| Todd Wood | Alimera Sciences | 54 | |
| Rich Cockrell | Alimera Sciences | N/A | |
| David Burke | Alimera Sciences | N/A | |
Management Performance
| Return On Asset | -0.38 |
Acura Pharmaceuticals Leadership Team
Elected by the shareholders, the Acura Pharmaceuticals' board of directors comprises two types of representatives: Acura Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acura. The board's role is to monitor Acura Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acura Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acura Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Ross, Independent Director | ||
| Robert Jones, CEO and President and Director | ||
| Bruce Wesson, Independent Director | ||
| Mr CPA, Treasurer VP | ||
| Peter Clemens, CFO, Principal Accounting Officer, Sr. VP and Secretary | ||
| Albert Brzeczko, VP of Technical Affairs | ||
| Immanuel Thangaraj, Independent Director | ||
| James Emigh, Vice President - Corporate Development | ||
| Robert Seiser, VP, Treasurer and Corporate Controller | ||
| Bradley Rivet, VP of Marketing | ||
| William Skelly, Independent Director |
Acura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Acura Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.38 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 3.49 M | ||||
| Shares Outstanding | 65.09 M | ||||
| Shares Owned By Insiders | 19.27 % | ||||
| Shares Owned By Institutions | 3.00 % | ||||
| Number Of Shares Shorted | 89.85 K | ||||
| Price To Earning | 125.00 X | ||||
| Price To Book | 24.11 X |
Pair Trading with Acura Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Acura Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acura Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acura Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acura Pharmaceuticals to buy it.
The correlation of Acura Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acura Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acura Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acura Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Acura OTC Stock
If you are still planning to invest in Acura Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acura Pharmaceuticals' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |